In BRAF inhibitor-resistant melanoma cells, small molecules such as the Caspase-3 agonist raptinal reversed the resistant phenotype by restoring GSDME expression, significantly enhancing tumor cell sensitivity to chemotherapeutic agents [77]. Here, BRAF is linked to melanoma.